CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Dako recently introduced in the United States its instant quality in situ hybridization, or IQISH, technology, which will reduce the turnaround time for cancer evaluation from two days to three and a half hours. HER2 IQFISH PharmDx, a fluorescence in situ hybridization assay, is the first product approved by the FDA that uses IQISH technology, which is based on the company’s fast IQISH hybridization buffer chemistry.
The assay improves the workflow in the pathology laboratory and is valuable in assessing patients for whom trastuzumab treatment is being considered. HER2 IQFISH PharmDx can support laboratories in identifying HER2 gene status with great accuracy and, now, speed.
“HER2 IQFISH PharmDx will provide more timely results, allowing us to incorporate FISH analysis into our routine workflow as easily as immuno- histochemistry,” Kenneth J. Bloom, MD, chief medical officer, Clarient Diagnostic Services, said in a statement.
HER2 IQFISH PharmDx has been sold in Europe and countries working with CE-labeling since February 2012.
Dako, 805-566-6655